April 29, 2020

Volition’s Nu. Q Vet Assay Detects Two Common Canine Cancers

VolitionRx Limited announced results from its first proof of concept study conducted by Texas A&M University. At a specificity of 90 percent, a single Nu.Q Vet assay detected almost 70 percent of both Canine Hemangiosarcoma and Canine Lymphoma with Areas Under the Curve of 84.5 percent and 83.1 percent cancer versus healthy, respectively. These two cancers alone represent almost a third of all canine cancers.

A presentation regarding Volition Veterinary Diagnostics Development is available to view here.

Commenting on the results, Dr. Heather Wilson-Robles, an Associate Professor at TAMU and Chief Medical Officer of Volition Veterinary Diagnostics said, “The proof of concept results in these two very prevalent canine cancers give us confidence to move forward with other Nu.Q Vet assays in our pipeline and with the larger range of cohorts and trials we have collected and planned. Clearly, we still have work to do as this single assay did not detect one of the other top five canine cancers, Canine Osteosarcoma, which was the third cancer tested in this study. However, I am delighted to see such positive results in these two significant cancers and look forward to reporting further data during the coming quarters with additional Nu.Q Vet assays, this time tested on an automated platform.”

Dr. Terry Kelly, Chief Scientific Officer of Volition America commented, “It is exciting to see such strong results from our first Nu.Q Vet study conducted at Texas A&M University Veterinary Hospital. It is also interesting to note the similar patterns of detection seen in both canine and human samples confirming that the Nu.Q platform does appear to be useful in more than just human diagnostics. As with human diagnostics, there are currently no accurate, simple, affordable cancer screening tests available in veterinary medicine and yet 25 percent of dogs will develop cancer at some stage of their life. I look forward to completing the planned trials and to launch our first Nu.Q Vet product in the US that we expect to occur in 2020.”

The US is currently the largest veterinary market in the world with almost 70 million pet dogs and approximately 6 million cancer diagnoses each year. It has a clearly defined regulatory pathway via the USDA, requiring fewer and smaller clinical studies than the FDA process for human diagnostics which generally allows a much faster route to revenue for veterinary products as compared to human products.

A presentation regarding Volition Veterinary Diagnostics Development is available to view here

For further details please contact mediarelations@volition.com.

Subscribe to Pet Insight